FA new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration (FDA) later this month.

Gilead's HIV drug lenacapavir earns FDA priority review after strong trial results, with the company planning to double U.S.

Later this month, the Food and Drug Administration is widely expected to approve a groundbreaking twice-yearly injection to ...

Walmart's Flipkart has secured a lending licence from the Indian central bank and banking regulator, enabling it to offer ...

A new injection to prevent HIV is expected to be approved by the U.S. Food and Drug Administration later this month.

NORTHAMPTON, MA / ACCESS Newswire / June 5, 2025 / At Gilead, we're advancing new ways to help end the HIV epidemic by ...

The Trump administration has moved to end funding for a broad swath of HIV vaccine research, saying current approaches are ...

GILD stock jumps 21.1% YTD as HIV dominance, lenacapavir progress, and liver drug approval offset oncology pressures. However ...

Shares of Gilead Sciences, Inc. (GILD) were in the spotlight on Friday morning after the company reportedly said that it ...

Gilead's twice-yearly HIV injection faces headwinds from US aid pullback. Gilead Sciences says it still plans to supply its ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Jefferies analyst Michael Yee reaffirmed a Buy rating on Gilead Sciences Inc. (NASDAQ:GILD), maintaining his price target at ...